Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.
Int J Mol Sci
; 21(9)2020 May 09.
Article
em En
| MEDLINE
| ID: mdl-32397531
ABSTRACT
The high occurrence of bladder cancer and its tendency to recur in combination with a lifelong surveillance make the treatment of superficial bladder cancer one of the most expensive and time-consuming. Moreover, carcinoma in situ often leads to muscle invasion with an unfavorable prognosis. Currently, invasive methods including cystoscopy and cytology remain a gold standard. The aim of this study was to explore urine-based biomarkers to find the one with the best specificity and sensitivity, which would allow optimizing the treatment plan. In this review, we sum up the current knowledge about Cytokeratin fragments (CYFRA 21.1), Excision Repair Cross-Complementation 1 (ERCC1), Tumour Protein p53 (Tp53), Fibroblast Growth Factor Receptor 3 (FGFR3), Tumor-Associated Trypsin Inhibitor (TATI) and their potential applications in clinical practice.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Carcinoma de Células de Transição
/
Biomarcadores Tumorais
/
Inibidor da Tripsina Pancreática de Kazal
/
Proteína Supressora de Tumor p53
/
Proteínas de Ligação a DNA
/
Endonucleases
/
Receptor Tipo 3 de Fator de Crescimento de Fibroblastos
/
Queratina-19
/
Antígenos de Neoplasias
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article